Valuation: Atossa Therapeutics, Inc.

Market Cap 19.56M 17.2M 16.27M 14.75M 27.71M 1.88B 27.87M 195M 75.22M 958M 73.43M 71.84M 3.08B P/E 2026 *
-0.51x
P/E 2027 * -0.62x
Enterprise Value 19.56M 17.2M 16.27M 14.75M 27.71M 1.88B 27.87M 195M 75.22M 958M 73.43M 71.84M 3.08B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.3%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Atossa Therapeutics, Inc.

1 day+3.16%
1 week-12.89%
Current month-21.60%
1 month-24.03%
3 months+4.26%
6 months-58.47%
Current year-77.85%
1 week 1.82
Extreme 1.82
2.26
1 month 1.82
Extreme 1.82
2.61
Current year 1.7
Extreme 1.7
10.95
1 year 1.7
Extreme 1.7
19.35
3 years 1.7
Extreme 1.7
34.65
5 years 1.7
Extreme 1.7
49.95
10 years 1.7
Extreme 1.7
468
Manager TitleAgeSince
Chief Executive Officer 75 31/03/2009
Director of Finance/CFO 50 13/10/2025
Chief Tech/Sci/R&D Officer - 30/09/2025
Director TitleAgeSince
Chairman 75 31/03/2009
Director/Board Member 64 31/03/2009
Director/Board Member 79 30/06/2011
Date Insider Type Main position Quantity % Market Cap. Importance
12/05/26
Ensisheim Partners LLC
OtherCompany 0 0% -
12/05/26 Free

Director

10,000 0.1161%
12/05/26 Free

Director

10,000 0.1161%
Change 5-day change 1-year change 3-year change Capi.($)
+3.16%-12.89%-84.78%-82.69% 18.96M
+2.64%+6.45%+11.87%+38.40% 47.97B
+0.22%+0.40%+50.91%+37.06% 44.5B
-1.58%+4.66%+359.34%+614.38% 43.93B
+1.70%+0.36%+12.56%+99.27% 41.03B
+0.51%-1.71%+5.18%+46.87% 29.85B
-0.48%-1.32%+23.98%+150.01% 17.27B
+0.08%+9.03%+8.41% - 15.34B
+1.76%+0.85%+29.13%+48.42% 15.3B
+1.97%-3.17% - - 14.82B
Average +1.00%+0.18%+46.29%+118.96% 27B
Weighted average by Cap. +0.74%+1.89%+79.46%+163.77%

Financials

2026 *2027 *
Net sales - -
Net income -34.89M -30.69M -29.02M -26.32M -49.43M -3.35B -49.72M -347M -134M -1.71B -131M -128M -5.49B -38.03M -33.44M -31.62M -28.68M -53.87M -3.65B -54.18M -379M -146M -1.86B -143M -140M -5.99B
Net Debt - -
Logo Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Employees
16
Date Price Change Volume
28/09/26 US$1.960 +3.16% 152,908
25/09/26 US$1.900 -7.32% 77,843
24/09/26 US$2.050 -5.96% 37,461
23/09/26 US$2.180 -3.54% 37,187
22/09/26 US$2.260 +0.44% 129,526
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.960USD
Average target price
18.67USD
Spread / Average Target
+852.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATOS Stock